cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-909Research ArticleИШЕМИЧЕСКАЯ БОЛЕЗНЬ СЕРДЦАCORONARY HEART DISEASEСвязь липопротеина(а) и аполипопротеина В как факторов риска с заболеваемостью ишемической болезнью сердца и развитием острого инфаркта миокардаLipoprotein(a) and apolipoprotein B as risk factors in coronary heart disease and acute myocardial infarction developmentАрабидзеГ. Г.ArabidzeG. G.arabidze@email.ruМосковский государственный медико-стоматологический университет, МоскваMoscow State Medico-Stomatological University, Moscow200520022005414955Copyright © Арабидзе Г.Г., 20052005Арабидзе Г.Г.Arabidze G.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/909

Цель. Выявить связи между ишемической болезнью сердца (ИБС) и уровнями липопротеина(а) — Лп(а), аполипопротеина В (апоВ), как значимым фактором риска (ФР). Материал и методы. Обследован 661 человек: 575 больных (302 мужчины, средний возраст 63,21±12,1 года и 273 женщины, средний возраст 69,57±10,85 года) с документально подтвержденной ИБС, также 86 человек (60 мужчин, средний возраст 37,41±12,26 года и 26 женщин, средний возраст 40,53±12,04 года без сердечно-сосудистых заболеваний. Определялись показатели липидного спектра — общий холестерин (ОХС), триглицериды (ТГ), Лп(а), апоВ. Результаты. Выявлена достоверность различий между обеими группами обследованных по t-тесту: для апоВ — р=0,0000; для Лп(а) — р=0,0069. Показатели Лп(а) и апоВ имеют выраженную корреляционную связь с другими общеизвестными параметрами липидного спектра плазмы крови у больных ИБС — ОХС, ТГ. Содержание апоВ (мг/дл) был достоверно выше у больных ИБС в сочетании с артериальной гипертонией (АГ) по сравнению с больными без АГ, а также у больных с передней локализацией острого инфаркта миокарда (ИМ). Заключение. Показатели липидного спектра Лп(а) и апоВ представляются достоверно значимыми ФР ИБС. Прямая корреляционная связь Лп(а) с ОХС появляется только у больных ИБС по сравнению с лицами без сердечно-сосудистых заболеваний. У больных ИБС с нормальными уровнями ОХС и ТГ повышение уровня апоВ>120 мг/дл представляется достоверно значимым ФР развития ИБС, особенно у больных АГ. Повышение концентрации апоВ достоверно связано с риском развития острого ИМ у больных ИБС, особенно передней локализации.

Aim. To investigate associations between coronary heart disease (CHD) and levels of lipoprotein(a), Lp(a), apolipoprotein B, apoB, as important risk factors (RF). Material and methods. The study included 661 participants: 575 patients with confirmed CHD (302 males; mean age 63.21±12.1 years; 273 females, mean age 69.57±10.85 years), and 86 individuals without cardiovascular disease (CVD) at baseline (60 males, mean age 37.41±12.26 years; 26 females, mean age 40.53±12.04 years). Lipid profile: total cholesterol (TCH), triglycerides (TG), Lp(a), apoB – was assessed. Results. Significant difference between two groups was observed in t-test: for apoB level p=0.0000; for Lp(a) p=0.0069. Lp(a) and apoB levels correlated with other standard parameters of lipid profile – TCH, TG. ApoB level (mg/dl) was significantly higher in CHD patients with arterial hypertension (AH) than in normotensive patients, as well as in participants with anterior acute myocardial infarction (MI). Conclusion. Lipid profile parameters Lp(a) and apoB are important RF of CHD. Positive correlation between Lp(a) and TCH levels was observed only in CHD patients, in comparison with CVD-free individuals. In CHD patients with normal TCH and TG levels, increased apoB concentration (>120 mg/dl) was an important RF of CHD development, especially in AH individuals. ApoB level increase significantly correlated with acute MI risk (anterior MI, in particular) in CHD patients.

ишемическая болезнь сердцаострый инфаркт миокардалипопротеин(а)аполипопротеин Вфакторы рискаcoronary heart diseaseacute myocardial infarctionlipoprotein(a)apolipoprotein Brisk factorsReferencesАфанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., Покровский С.Н. Иммуноферментный метод определения липопротеида(а). Бюлл экспер биол мед 1995; 4: 398-401.Афанасьева О.И., Адамова И.Ю., Беневоленская Г.Ф., Покровский С.Н. Иммуноферментный метод определения липопротеида(а). Бюлл экспер биол мед 1995; 4: 398-401.Ежов М.В., Кононова О.И., Миронова И.Ю. и др. Влияют ли аскорбиновая кислота, лизин и их сочетание на уровень липопротеида(а) у больных ИБС? Кардиология 1996; 9: 31-3.Ежов М.В., Кононова О.И., Миронова И.Ю. и др. Влияют ли аскорбиновая кислота, лизин и их сочетание на уровень липопротеида(а) у больных ИБС? Кардиология 1996; 9: 31-3.Томпсон Г.Р. Руководство по гиперлипидемии. Лондон: Yugoslavia: Current Science 1991; 255с.Томпсон Г.Р. Руководство по гиперлипидемии. Лондон: Yugoslavia: Current Science 1991; 255с.Amemiya H, Arinami Т, Kikuchi S, et al. Apolipoprotein(a) size and pentanucleotide repeat polymorphisms are associated with degree of atherosclerosis in coronary artery disease. Atherosclerosis 1996; 123: 181-91.Amemiya H, Arinami Т, Kikuchi S, et al. Apolipoprotein(a) size and pentanucleotide repeat polymorphisms are associated with degree of atherosclerosis in coronary artery disease. Atherosclerosis 1996; 123: 181-91.Berg K. A new serum type system in men - the Lp(a) system. Acta Path Microbiol Scand 1963; 59: 369-82.Berg K. A new serum type system in men - the Lp(a) system. Acta Path Microbiol Scand 1963; 59: 369-82.Bostom AG, Gagnon DR, Cupples A, et al. A prospective investigation of elevated lipoprotein(a) levels detected by electrophoresis and cardiovascular disease in women. Circulation. 1994; 90: 1688-95.Bostom AG, Gagnon DR, Cupples A, et al. A prospective investigation of elevated lipoprotein(a) levels detected by electrophoresis and cardiovascular disease in women. Circulation. 1994; 90: 1688-95.Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA.1996; 276: 544-8.Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA.1996; 276: 544-8.Bostom AG, Hume AL, Eaton CB, et al. The effect of high dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease. Pharmacotherapy 1995; 15: 458-64.Bostom AG, Hume AL, Eaton CB, et al. The effect of high dose ascorbate supplementation on plasma lipoprotein(a) levels in patients with premature coronary heart disease. Pharmacotherapy 1995; 15: 458-64.Budde Т, Fechtrup C, Bosenberg E, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinical suspected coronary atherosclerosis. Arterioscler. Thromb 1994; 14: 1730-6.Budde Т, Fechtrup C, Bosenberg E, et al. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinical suspected coronary atherosclerosis. Arterioscler. Thromb 1994; 14: 1730-6.Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteis with coronary artery disease documented by angiography. Circulation 1986; 74(4): 758-65.Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteis with coronary artery disease documented by angiography. Circulation 1986; 74(4): 758-65.Fujiwara R, Kutsumi Y, Hayoshi T, et al. Relation of angiographically defined coronary artery disease and plasma concentrations of insulin, lipid, and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance. Am J Cardiol 1995; 75-6.Fujiwara R, Kutsumi Y, Hayoshi T, et al. Relation of angiographically defined coronary artery disease and plasma concentrations of insulin, lipid, and apolipoprotein in normolipidemic subjects with varying degrees of glucose tolerance. Am J Cardiol 1995; 75-6.Jauhiainen M, Koskinen P, Ehnholm С, et al. Lipoprotein (a) and coronary disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.Jauhiainen M, Koskinen P, Ehnholm С, et al. Lipoprotein (a) and coronary disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation1993; 87: 1135-41.Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex and menopausal status on plasma lipoprotein(a) levels. The Framingham Offspring Study. Circulation1993; 87: 1135-41.Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein(a) concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995; 26: 1841-8.Jurgens G, Taddei-Peters WC, Koltringer P, et al. Lipoprotein(a) concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995; 26: 1841-8.Klausen IC, Beusiegel U, Menzel H-J, et al. Apo(a) phenotypes and Lp(a) concentration in offspring of men with and without myocardial infarction. The EARS Study. Arterioscler Thromb Vase Biol 1995; 15: 1001-8.Klausen IC, Beusiegel U, Menzel H-J, et al. Apo(a) phenotypes and Lp(a) concentration in offspring of men with and without myocardial infarction. The EARS Study. Arterioscler Thromb Vase Biol 1995; 15: 1001-8.Kostner G, Klein G, Krempler F. Can serum Lp(a) concentration be lowered by drugs and/or diet? In: Treatment of hyperlipoproteinemia. Carlson LA, Olsson AG (Ed.). New York, Raven Press 1984: 151-6.Kostner G, Klein G, Krempler F. Can serum Lp(a) concentration be lowered by drugs and/or diet? In: Treatment of hyperlipoproteinemia. Carlson LA, Olsson AG (Ed.). New York, Raven Press 1984: 151-6.Lamarche B, Tchernof A, Mauriege P, et al. Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size fs Risk Factors for Ischemic Heart Disease. JAMA 1998; 279; 24: 1955-61.Lamarche B, Tchernof A, Mauriege P, et al. Fasting Insulin and Apolipoprotein B Levels and Low-Density Lipoprotein Particle Size fs Risk Factors for Ischemic Heart Disease. JAMA 1998; 279; 24: 1955-61.Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229-35.Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995; 6: 229-35.Manfroi WC, Zago AJ, Campos M, et al. Are apolipoproteins A and B better than lipoproteins assessing risk of obstructive coronary heart disease? Arq Bras Cardiol 2004; 38: 26-34.Manfroi WC, Zago AJ, Campos M, et al. Are apolipoproteins A and B better than lipoproteins assessing risk of obstructive coronary heart disease? Arq Bras Cardiol 2004; 38: 26-34.National Cholesterol Education Program.Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Circulation 1994; 89: 1329-445.National Cholesterol Education Program.Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Circulation 1994; 89: 1329-445.Nestel PJ. Is serum triglyceride an independent ptedictor of coronary artery disease? Pract Cardiol 1987; 13: 96-101.Nestel PJ. Is serum triglyceride an independent ptedictor of coronary artery disease? Pract Cardiol 1987; 13: 96-101.Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997; 96: 1390-7.Nguyen TT, Ellefson RD, Hodge DO, et al. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 1997; 96: 1390-7.Orth-Gomer K, Mittleman M, Schenk-Gustaffson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-34.Orth-Gomer K, Mittleman M, Schenk-Gustaffson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997; 95: 329-34.Sewdarsen M, Desai RK, Vythilingum S, et al. Serum lipoproteins and apolipoproteins in young normocholesterolaemic, nondiabetic Indian men with myocardial infarction. Postgrad Med J 1991; 67: 14-5.Sewdarsen M, Desai RK, Vythilingum S, et al. Serum lipoproteins and apolipoproteins in young normocholesterolaemic, nondiabetic Indian men with myocardial infarction. Postgrad Med J 1991; 67: 14-5.Sigurdsson G, Baldursdottir A, Sigvaldason H, et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992; 69: 1251-4.Sigurdsson G, Baldursdottir A, Sigvaldason H, et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992; 69: 1251-4.Skalen K, Gustafsson M, Rydberg EK, et al. Subendotelial retention of aterogenic lipoproteins in early aterosclerosis. Nature 2002; 417(6890): 750-4.Skalen K, Gustafsson M, Rydberg EK, et al. Subendotelial retention of aterogenic lipoproteins in early aterosclerosis. Nature 2002; 417(6890): 750-4.Sniderman AD, Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias. Clin Chem 1996; 42: 489-91.Sniderman AD, Cianflone K. Measurement of apoproteins: time to improve the diagnosis and treatment of the atherogenic dyslipoproteinemias. Clin Chem 1996; 42: 489-91.Shaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994; 271: 999-1003.Shaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994; 271: 999-1003.Thompson GR, Maher VMG, Matthews S, et al. Familial hypercholesterolaemia regression study: a randomized trial of LDL apheresis. Lancet 1995; 345: 811-6.Thompson GR, Maher VMG, Matthews S, et al. Familial hypercholesterolaemia regression study: a randomized trial of LDL apheresis. Lancet 1995; 345: 811-6.Winder AF. Lipoprotein Lp(A) and the Apolipoproteins. In Cardiovascular disease: Risk factors and intervention. Poulter N, Sever P, Thom S (Ed.). Oxford, Radcliffe Med Press 1993; 129-37.Winder AF. Lipoprotein Lp(A) and the Apolipoproteins. In Cardiovascular disease: Risk factors and intervention. Poulter N, Sever P, Thom S (Ed.). Oxford, Radcliffe Med Press 1993; 129-37.

The authors declare that there are no conflicts of interest present.